Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1)
—Designation Follows Recently Reported PHYOX™1 Phase 1 Data Showing Positive Clinical Responses to DCR-PHXC— —FDA Recognizes Primary Hyperoxaluria Types 2 and 3 (PH2 and PH3) as Meeting Criteria for a Serious or Life-Threatening Disease or Condition— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
— Company Submitted Clinical Trial Application and Plans to Initiate Multicenter Phase 1/2 Trial in Third Quarter of 2019 — — Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Program Broadens Dicerna’s Commitment to Addressing Chronic Liver Diseases— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the...
View HTML
Toggle Summary Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2019-- Dicerna TM Pharmaceuticals, Inc....
View HTML
Toggle Summary Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
– Prof. Bernd Hoppe , M.D., Appointed Vice President, Global Medical Affairs at Dicerna – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)...
View HTML
Toggle Summary Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
— Steven Kates , Ph.D., Joins Company as Vice President, Regulatory Affairs — — David Caponera Appointed Head of Patient Advocacy and Patient Services — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading...
View HTML
Toggle Summary Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
— Company Expands Management Team and Bolsters Commercial Capabilities to Support Continued Growth — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at the Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML
Toggle Summary Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus
— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2019-- Dicerna Pharmaceuticals, Inc . (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today...
View HTML